Weiss J, Wright G, Bekkers A C, van den Bergh C J, Verheij H M
Department of Microbiology, New York University School of Medicine, New York 10016.
J Biol Chem. 1991 Mar 5;266(7):4162-7.
Phospholipases A2 (PLA-2) are conserved enzymes that can vary widely in their activity toward certain biological targets. Activity of PLA-2 toward Escherichia coli treated with the bactericidal/permeability-increasing protein (BPI) of granulocytes has been detected only in "Group II" PLA-2 (lacking Cys11-Cys77) and correlates with overall basicity and the presence of a cluster of basic amino acids within a variable surface region near the NH2 terminus (including residues 6, 7, 10, 11, and 15). We now show that of five pancreatic PLA-2 ("Group I" enzymes) tested from different species of mammals, the human enzyme that is most basic both globally (pI 8.7) and locally (Arg-6, Lys-7, and Lys-10) is active toward BPI-treated E. coli (approximately 1-2% activity of the most active Group II PLA-2) whereas the other four PLA-2 are essentially inactive (less than 0.1%). The cDNA of the pig pancreatic PLA-2 (pI 6.4; Arg-6, Ser-7, Lys-10) has been modified by site-specific mutagenesis and the wild-type and mutant PLA-2 have been expressed in and purified from either E. coli or Saccharomyces cerevisiae to determine more precisely the structural determinants of PLA-2 activity toward BPI-treated E. coli. The single substitution of lysine (or arginine) for Ser-7 transformed the pig pancreatic PLA-2 into an active enzyme toward BPI-treated E. coli possessing 25-50% the activity of the human PLA-2. Additional modifications to increase global basicity (increase in net charge up to +4) caused a further (up to 2-fold) increase in activity. All mutant PLA-2 still containing Ser-7 possessed little or no activity toward BPI-treated E. coli. Changes in activity toward BPI-treated E. coli were accompanied by parallel changes in enzyme binding to this target. In contrast, substitution of lysine (or arginine) for Ser-7 caused little or no alteration of enzyme activity toward either autoclaved E. coli or egg yolk lipoproteins indicating no major effects on the catalytic properties of the PLA-2. This study demonstrates directly the role of NH2-terminal basic residues in the action of PLA-2 on BPI-treated E. coli and suggests that these properties mainly facilitate PLA-2 binding to this biological target.
磷脂酶A2(PLA - 2)是保守的酶,其对某些生物靶点的活性差异很大。仅在“II组”PLA - 2(缺乏Cys11 - Cys77)中检测到PLA - 2对用粒细胞杀菌/通透性增加蛋白(BPI)处理的大肠杆菌的活性,且该活性与整体碱性以及NH2末端附近可变表面区域内碱性氨基酸簇的存在相关(包括第6、7、10、11和15位残基)。我们现在表明,在从不同哺乳动物物种测试的五种胰腺PLA - 2(“I组”酶)中,在整体(pI 8.7)和局部(Arg - 6、Lys - 7和Lys - 10)上碱性最强的人源酶对经BPI处理的大肠杆菌有活性(约为活性最高的II组PLA - 2活性的1 - 2%),而其他四种PLA - 2基本无活性(低于0.1%)。猪胰腺PLA - 2(pI 6.4;Arg - 6、Ser - 7、Lys - 10)的cDNA已通过定点诱变进行修饰,野生型和突变型PLA - 2已在大肠杆菌或酿酒酵母中表达并纯化,以更精确地确定PLA - 2对经BPI处理的大肠杆菌活性的结构决定因素。将Ser - 7的丝氨酸替换为赖氨酸(或精氨酸)可使猪胰腺PLA - 2转变为对经BPI处理的大肠杆菌有活性的酶,其活性为人源PLA - 2的25 - 50%。为增加整体碱性(净电荷增加至 +4)进行的其他修饰导致活性进一步(高达2倍)增加。所有仍含有Ser - 7的突变型PLA - 2对经BPI处理的大肠杆菌几乎没有或没有活性。对经BPI处理的大肠杆菌活性的变化伴随着酶与该靶点结合的平行变化。相比之下,将Ser - 7的丝氨酸替换为赖氨酸(或精氨酸)对经高压灭菌的大肠杆菌或蛋黄脂蛋白的酶活性几乎没有改变,表明对PLA - 2的催化特性没有重大影响。这项研究直接证明了NH2末端碱性残基在PLA - 2对经BPI处理的大肠杆菌作用中的作用,并表明这些特性主要促进PLA - 2与该生物靶点的结合。